Literature DB >> 7430415

Methadone-disulfiram interaction during methadone maintenance.

T G Tong, N L Benowitz, M J Kreek.   

Abstract

In an attempt to characterize a possible drug interaction between methadone and disulfiram, 500 mg/day insulfiram was administered orally for seven days to seven subjects on methadone maintenance. Plasma methadone concentrations and urinary excretion of methadone and its pyrrolidine and pyrrolidone metabolites were measured and subjective symptoms of opiate intoxication and abstinence were noted before, during, and after disulfiram administration. Mean trough plasma methadone concentrations and terminal half-lives were lowest and shortest during disulfiram treatment, although this finding was not statistically significant. The ratio of urinary methadone to its pyrrolidine metabolite decreased during disulfiram treatment in all subjects. There is no evidence to support our original hypothesis that disulfiram might inhibit methadone metabolism. In contrast, urinary excretion of the major pyrrolidine metabolite increased relative to excretion of methadone. This suggests enhanced N-demethylation during disulfiram treatment. Disulfiram had no effect on opiate intoxication or abstinence symptoms. Disulfiram may alter methadone disposition, but in this study it was shown that in doses used for management of alcoholism there was no significant interaction between disulfiram and methadone.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7430415     DOI: 10.1002/j.1552-4604.1980.tb02543.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

Review 1.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 2.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Steady-state pharmacokinetics of methadone in opioid addicts.

Authors:  K Wolff; A W Hay; D Raistrick; R Calvert
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  Pharmacotherapy in the treatment of addiction: methadone.

Authors:  Mary Jeanne Kreek; Lisa Borg; Elizabeth Ducat; Brenda Ray
Journal:  J Addict Dis       Date:  2010-04

5.  Prevalence of Heavy Alcohol Use Among People Receiving Methadone Following Change to Methadose.

Authors:  Jan Klimas; Evan Wood; Ekaterina Nosova; M-J Milloy; Thomas Kerr; Kanna Hayashi
Journal:  Subst Use Misuse       Date:  2017-06-12       Impact factor: 2.164

6.  Effects of disulfiram on QTc interval in non-opioid-dependent and methadone-treated cocaine-dependent patients.

Authors:  Thomas S Atkinson; Nichole Sanders; Michael Mancino; Alison Oliveto
Journal:  J Addict Med       Date:  2013 Jul-Aug       Impact factor: 3.702

Review 7.  Treatment of opioid-dependent pregnant women: clinical and research issues.

Authors:  Hendree E Jones; Peter R Martin; Sarah H Heil; Karol Kaltenbach; Peter Selby; Mara G Coyle; Susan M Stine; Kevin E O'Grady; Amelia M Arria; Gabriele Fischer
Journal:  J Subst Abuse Treat       Date:  2008-01-14

Review 8.  What we have learned from the Methadone Maintenance Treatment of Dual Disorder Heroin Use Disorder patients.

Authors:  Angelo G I Maremmani; Matteo Pacini; Icro Maremmani
Journal:  Int J Environ Res Public Health       Date:  2019-02-03       Impact factor: 3.390

Review 9.  Practical considerations for the clinical use of buprenorphine.

Authors:  Hendree E Jones
Journal:  Sci Pract Perspect       Date:  2004-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.